Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease
Main finding · All-cause ED encounters or hospitalizationsResult — go to the resultHazard ratio 0.90 95% CI 0.87–0.94Authors' conclusion
GLP-1RA initiation was associated with a reduction in all-cause ED visits and hospitalizations compared with new use of a DPP4i.
Study context
- Population
- Adults with eGFR <90 mL/min/1.73 m²
- Participants
- 24,576 vs 23,600
- Exposure
- GLP-1 RA vs DPP-4i initiation
- GLP-1RAn = 24,576
- DPP4in = 23,600reference
- Outcome
- All-cause emergency department (ED) encounters or hospitalizations
Methodological detailsinverse probability of treatment weighting, new-user design
- Inverse probability of treatment weighting
- New-user design
Main finding
As reported in the abstract
Hazard ratio
0.90
95% CI 0.87–0.94
P < 0.0001
GLP-1RAvs DPP4i
HR 0.90 (95% CI 0.87–0.94); P < 0.0001
Observational data: associations, not effects.
Further findings
Confirmatory analyses (Andersen-Gill model; Prentice-Williams-Peterson (PWP) calendar time model)
- Finding consistent in confirmatory analyses
Original publication
Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease. Diabetes Care. Published 26 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →